Aera Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $193M
Overview
A biotech firm developing next-generation delivery platforms for genetic medicines using synthetic biology.
Gene TherapyRare Diseases
Technology Platform
A synthetic biology platform for engineering programmable viral and non-viral delivery vectors to improve targeting and safety of genetic medicines.
Funding History
1Total raised:$193M
Series A$193M
Opportunities
The urgent need for better delivery systems in the booming gene therapy market presents a massive partnership and licensing opportunity.
Risk Factors
High technical risk in developing novel vectors that must demonstrate clear advantages over established, albeit imperfect, delivery methods.
Competitive Landscape
Competes with other delivery-focused biotechs like Dyno Therapeutics and existing LNP developers, as well as large caps improving AAV technologies.